Drug Profile
Research programme: Staphylococcus epidermidis monoclonal antibodies - Inhibitex
Alternative Names: SdrG; SdrG mAb; SE-mAbLatest Information Update: 13 Jul 2009
Price :
$50
*
At a glance
- Originator Inhibitex
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 13 Jul 2009 Discontinued - Preclinical for Staphylococcal infections in USA (Parenteral)
- 21 Aug 2007 Preclinical development is ongoing
- 21 Aug 2007 This research programme is available for licensing (http://www.inhibitex.com)